✦ LIBER ✦

Histomorphometric evaluation of daily and intermittent oral ibandronate in women with postmenopausal osteoporosis: results from the BONE study

✍ Scribed by R.R. Recker; R.S. Weinstein; C.H. Chesnut; R.C. Schimmer; P. Mahoney; C. Hughes; B. Bonvoisin; P.J. Meunier

Publisher: Springer-Verlag
Year: 2004
Tongue: English
Weight: 205 KB
Volume: 15
Category: Article
ISSN: 0937-941X
DOI: 10.1007/s00198-003-1530-0

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Daily and intermittent oral ibandronate

Daily and intermittent oral ibandronate normalize bone turnover and provide significant reduction in vertebral fracture risk: results from the BONE study

✍ P. D. Delmas; R. R. Recker; C. H. Chesnut; A. Skag; J. A. Stakkestad; R. Emkey; 📂 Article 📅 2004 🏛 Springer-Verlag 🌐 English ⚖ 221 KB

Intravenous ibandronate injections in po

Intravenous ibandronate injections in postmenopausal women with osteoporosis: One-year results from the dosing intravenous administration study

✍ Pierre D. Delmas; Silvano Adami; Cezary Strugala; Jacob A. Stakkestad; Jean-Yves 📂 Article 📅 2006 🏛 John Wiley and Sons 🌐 English ⚖ 185 KB

## Abstract ## Objective Although oral bisphosphonates are effective treatments for postmenopausal women with osteoporosis, oral dosing may be unsuitable for some patients. An efficacious intravenously administered bisphosphonate could be beneficial for such patients. Ibandronate, a potent nitroge

Effects of Raloxifene on Fracture Severi

Effects of Raloxifene on Fracture Severity in Postmenopausal Women with Osteoporosis: Results from the MORE Study

✍ E. Siris; J. D. Adachi; Y. Lu; T. Fuerst; G. G. Crans; M. Wong; K. D. Harper; H. 📂 Article 📅 2002 🏛 Springer-Verlag 🌐 English ⚖ 104 KB

Osteoporosis and rate of bone loss among

Osteoporosis and rate of bone loss among postmenopausal survivors of breast cancer : Results from a subgroup in the Women's Health Initiative Observational Study

✍ Zhao Chen; Michael Maricic; Mary Pettinger; Cheryl Ritenbaugh; Ana Maria Lopez; 📂 Article 📅 2005 🏛 John Wiley and Sons 🌐 English ⚖ 196 KB 👁 3 views

Five years of denosumab exposure in wome

Five years of denosumab exposure in women with postmenopausal osteoporosis: Results from the first two years of the FREEDOM extension

✍ Socrates Papapoulos; Roland Chapurlat; Cesar Libanati; Maria Luisa Brandi; Jacqu 📂 Article 📅 2012 🏛 American Society for Bone and Mineral Research 🌐 English ⚖ 256 KB 👁 1 views

The 3-year FREEDOM trial assessed the efficacy and safety of 60 mg denosumab every 6 months for the treatment of postmenopausal women with osteoporosis. Participants who completed the FREEDOM trial were eligible to enter an extension to continue the evaluation of denosumab efficacy and safety for up

Effect of raloxifene on bone mineral den

Effect of raloxifene on bone mineral density and biochemical markers of bone turnover in Japanese postmenopausal women with osteoporosis: results from a randomized placebo-controlled trial

✍ H. Morii; Y. Ohashi; Y. Taketani; M. Fukunaga; T. Nakamura; A. Itabashi; S. Sark 📂 Article 📅 2003 🏛 Springer-Verlag 🌐 English ⚖ 268 KB